Howard J. Rosen MD
Associate Professor, Neurology, UCSF School of Medicine
Join to view full profile
400 Parnassus AveSan Francisco, CA 94143
Phone+1 415-476-6880
Fax+1 415-476-4150
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 4 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Howard Rosen, MD is a board certified neurologist in San Francisco, California. He is currently licensed to practice medicine in California. He is an Associate Professor at UCSF School of Medicine.
Education & Training
University of California (San Francisco)Residency, Neurology, 1993 - 1996
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1989 - 1992
Boston University School of MedicineClass of 1989
Certifications & Licensure
CA State Medical License 1993 - 2027- CA State Medical License 1993 - 2027
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016
Publications & Presentations
PubMed
- Reduced levels of angiogenesis biomarkers predict increased symptom severity in Chinese Americans with Alzheimer's disease with demographic-specific effect.Taylor P Johnson, Elena Tsoy, Jeffrey Shen, Will Rivera, Kevin Lieu
Neurocase. 2025-04-01 - 32 citationsDetection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers.Lawren VandeVrede, Hanna Cho, Mark Sanderson-Cimino, Fattin Wekselman, Yann Cobigo
JAMA Neurology. 2025-02-10 - 10 citationsClinical and neuropathological associations of plasma Aβ/Aβ, p-tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders.Binita Rajbanshi, Igor Prufer Q C Araujo, Lawren VandeVrede, Peter A Ljubenkov, Adam M Staffaroni
Alzheimer's & Dementia. 2025-01-29
Press Mentions
This COVID-19 Practice: As the Pandemic Cancels Large in-Person Events, Neurology Conferences Go VirtualJune 12th, 2020
NIH-Funded Research Consortium to Target Frontotemporal Lobar DegenerationOctober 16th, 2019
Grant Support
- ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)MAYO CLINIC ROCHESTER2019–2030
- ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)MAYO CLINIC ROCHESTER2019–2030
- ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)MAYO CLINIC ROCHESTER2019–2030
- Multidisciplinary Research Fellowship in Alzheimer’s disease and Related DementiasUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2005–2030
- Multidisciplinary Research Fellowship in Alzheimer’s disease and Related DementiasUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2005–2030
